These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 8690621)
1. Efficacy of combination therapy with insulin and oral hypoglycemic agents in patients with type II diabetes during a 1-year period. Mozersky RP; Patel H; Bahl VK; Bahl S; Mook W J Am Osteopath Assoc; 1996 Jun; 96(6):346-51. PubMed ID: 8690621 [TBL] [Abstract][Full Text] [Related]
2. Increased complications in noninsulin-dependent diabetic patients treated with insulin versus oral hypoglycemic agents: a population study. Savage S; Estacio RO; Jeffers B; Schrier RW Proc Assoc Am Physicians; 1997 Mar; 109(2):181-9. PubMed ID: 9069587 [TBL] [Abstract][Full Text] [Related]
3. Effects of insulin-oral hypoglycemic agents combined therapy in outpatients with type 2 diabetes. Sinagra D; Scarpitta AM; Amato M Eur Rev Med Pharmacol Sci; 1998; 2(5-6):175-9. PubMed ID: 10710815 [TBL] [Abstract][Full Text] [Related]
4. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs. Yang W; Ji Q; Zhu D; Yang J; Chen L; Liu Z; Yu D; Yan L Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073 [TBL] [Abstract][Full Text] [Related]
5. Response of regimens of insulin therapy in type 2 diabetes mellitus subjects with secondary failure. Zargar AH; Masoodi SR; Laway BA; Wani AI; Bashir MI J Assoc Physicians India; 2002 May; 50(5):641-6. PubMed ID: 12186116 [TBL] [Abstract][Full Text] [Related]
6. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study. Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471 [TBL] [Abstract][Full Text] [Related]
7. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. Yki-Järvinen H Diabetes Metab Res Rev; 2002; 18 Suppl 3():S77-81. PubMed ID: 12324990 [TBL] [Abstract][Full Text] [Related]
8. Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy? Spoelstra JA; Stolk RP; Heerdink ER; Klungel OH; Erkens JA; Leufkens HG; Grobbee DE Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):121-7. PubMed ID: 12642975 [TBL] [Abstract][Full Text] [Related]
9. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus. Ponssen HH; Elte JW; Lehert P; Schouten JP; Bets D Clin Ther; 2000 Jun; 22(6):709-18. PubMed ID: 10929918 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Goldberg RB; Fonseca VA; Truitt KE; Jones MR Arch Intern Med; 2008 Jul; 168(14):1531-40. PubMed ID: 18663165 [TBL] [Abstract][Full Text] [Related]
11. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. Peters Harmel AL; Kendall DM; Buse JB; Boyle PJ; Marchetti A; Lau H Curr Med Res Opin; 2004; 20(2):215-23. PubMed ID: 15006017 [TBL] [Abstract][Full Text] [Related]
12. An intensified lifestyle intervention programme may be superior to insulin treatment in poorly controlled Type 2 diabetic patients on oral hypoglycaemic agents: results of a feasibility study. Aas AM; Bergstad I; Thorsby PM; Johannesen O; Solberg M; Birkeland KI Diabet Med; 2005 Mar; 22(3):316-22. PubMed ID: 15717881 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P; Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112 [TBL] [Abstract][Full Text] [Related]
14. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476 [TBL] [Abstract][Full Text] [Related]
15. Combination therapy of glibenclamide and insulin in NIDDM patients with secondary failure to oral drugs. Mohan V; Snehalatha C; Ramachandran A; Viswanathan M J Assoc Physicians India; 1990 Aug; 38(8):537-41. PubMed ID: 2123183 [TBL] [Abstract][Full Text] [Related]
16. The beta cell function in NIDDM patients with secondary failure: a three year follow-up of combined oral hypoglycemic and insulin therapy. Greco AV; Caputo S; Bertoli A; Ghirlanda G Horm Metab Res; 1992 Jun; 24(6):280-3. PubMed ID: 1634193 [TBL] [Abstract][Full Text] [Related]
17. [Renewal of oral therapy for diabetes mellitus after secondary failure]. Guberman D Harefuah; 1989 Nov; 117(9):240-1. PubMed ID: 2693275 [TBL] [Abstract][Full Text] [Related]
18. [Changes in metabolic control after interruption of oral hypoglycemic agents in type II diabetic patients with secondary failure during combined therapy]. De Mattia G; Laurenti O; Tullo MG; Ventura C; Albi F Clin Ter; 1988 Oct; 127(2):119-22. PubMed ID: 2976347 [No Abstract] [Full Text] [Related]